Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Australia's new medical device rules open way to full EU MRA (mutual recognition agreement)

This article was originally published in Clinica

Executive Summary

After a series of delays Australia at last implemented its new medical device regulatory system on October 4. The new law removes the obstacles to the EU implementing for its part the mutual recognition agreement (MRA) with Australia. The MRA is already in operation in Australia, where the TGA, the Australian regulatory authority, has issued several certificates to the EU regulatory system. But the EU has said that it would not operate the system until the new Australian medical device law is voted and implemented and in harmony with the EU requirements.

You may also be interested in...



Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line

The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.

Global Pharma Guidance Tracker – March 2024

Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials

Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT068450

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel